Somatostatin and somatostatin agonists for decreasing body...

Details Somatostatin and somatostatin agonists for decreasing body... Somatostatin and somatostatin agonists for decreasing body...

2006-04-25

2006-04-25

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S011400, C514S012200, C514S021800, C424S177100, C435S007100, C435S325000, C530S300000, C530S311000, C530S350000

Reexamination Certificate

active

07034003

ABSTRACT:
The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction of body weight in a human or mammalian animal.

REFERENCES:
patent: 4133782 (1979-01-01), Vale et al.
patent: 4146612 (1979-03-01), Veber
patent: 4190575 (1980-02-01), Sarantakis
patent: 4190648 (1980-02-01), Veber
patent: 4209426 (1980-06-01), Sarantakis
patent: 4211693 (1980-07-01), Rivier et al.
patent: 4215039 (1980-07-01), Sarantakis
patent: 4224199 (1980-09-01), Meyers et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4238481 (1980-12-01), Rink et al.
patent: 4261885 (1981-04-01), Sakakibara et al.
patent: 4282143 (1981-08-01), Sarantakis
patent: 4291022 (1981-09-01), Sandrin et al.
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 4316890 (1982-02-01), Kamber et al.
patent: 4328214 (1982-05-01), Rink et al.
patent: 4358439 (1982-11-01), Sieber et al.
patent: 4360516 (1982-11-01), Freidinger et al.
patent: 4369179 (1983-01-01), Rink et al.
patent: 4395403 (1983-07-01), Bauer et al.
patent: 4435385 (1984-03-01), Bauer et al.
patent: 4485101 (1984-11-01), Coy et al.
patent: 4486415 (1984-12-01), Freidinger
patent: 4522813 (1985-06-01), Nutt
patent: 4585755 (1986-04-01), Morgan et al.
patent: 4603120 (1986-07-01), Kamber
patent: 4650787 (1987-03-01), Schally et al.
patent: 4684620 (1987-08-01), Hruby et al.
patent: 4725577 (1988-02-01), Schally et al.
patent: 4728638 (1988-03-01), Bauer et al.
patent: 4853371 (1989-08-01), Coy et al.
patent: 4871717 (1989-10-01), Coy et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5506339 (1996-04-01), Coy et al.
patent: 5583104 (1996-12-01), LaRusso
patent: 5708135 (1998-01-01), Coy et al.
patent: 5763200 (1998-06-01), Dunmore et al.
patent: 0 083 305 (1983-07-01), None
patent: 0 030 920 (1984-02-01), None
patent: 0 203 031 (1986-11-01), None
patent: 0 329 295 (1989-08-01), None
patent: 0 363 589 (1990-04-01), None
patent: 0 389 180 (1990-09-01), None
patent: 0 505 680 (1992-09-01), None
patent: 0657174 (1995-06-01), None
patent: 2 522 655 (1983-09-01), None
patent: 2 095 261 (1982-09-01), None
patent: 88/02756 (1988-04-01), None
patent: 88/05052 (1988-07-01), None
patent: 90/12811 (1990-11-01), None
patent: 91/09056 (1991-06-01), None
patent: WO 91/18016 (1991-11-01), None
patent: WO9635950 (1996-11-01), None
patent: WO 97/01579 (1997-01-01), None
patent: WO9711962 (1997-04-01), None
patent: WO9809991 (1998-03-01), None
patent: WO9810786 (1998-03-01), None
Lloyd et al. (American Physiological Society, vol. 268, pp. G102-106, 1995).
Carretta, R. et al., “Reduction of Blood Pressure in Obese Hyperinsulinaemic Hypertensive Patients During Somatostatin Infusion”, Journal of Hypertension, 7(6):S196-S197 (1989).
Clark, J. A. et al., “Multiple Regions of Ligand Discrimination Revealed by Analysis of Chimeric Parathyroid Hormone 2 (PTH2) and PTH/PTH-Related Peptide (PTHrP) Receptors”, Molecular Endocrinology, 12(2):193-206 (1998).
Huang, H.-J. et al., “ Hyperamylinemia, Hyperinsulinemia, and Insulin Resistance in Genetically Obese LA/N-cp Rats”, Supplement to Hypertension, 19(1):I-101-I109 (1992).
Lunetta, M. et al., “Long-Term Octreotide Treatment Reduced Hyperinsulinemia, Excess Body Weight and Skin Lesions in Severe Obesity With Acanthosis Nigricans”, J. Endocrinol. Invest., 19:699-703 (1996).
Van Binst, G. et al., “Backbone Modifications in Somatostatin Analogues: Relation Between Conformation and Activity”, Peptide Research, 5(1):8-13 (1992).
Zamboni, M. et al., “Obesity and Regional Body-Fat Distribution in Men: Separate and Joint Relationships to Glucose Tolerance and Plasma Lipoproteins”,Am J Clin. Nutrition,60:682-687 (1994).
Horvath, A. et al., “Conformations of somatostatin analogues having antitumor activity,” Peptides, 1992, Proceedings of the 22ndEuropean Peptide Symposium, Sep. 13-19, 1992 Interlaken, Switzerland, p 533-534.

Affiliated with

Also associated with

Rating

Somatostatin and somatostatin agonists for decreasing body... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Somatostatin and somatostatin agonists for decreasing body..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin and somatostatin agonists for decreasing body... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3607865